PRNewsWire - Health

Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update
Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression
YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia
OMRON Healthcare spendet 4.000 Blutdruckmessgeräte und verbessert AFib-Screening mit AI-basierter Intellisense AFib-Technologie